qXR-CTR vs Lung Density Analysis
AI Verdict
Choose qXR-CTR if…
Choose qXR-CTR if your primary need is an automated, rapid assessment of heart size and potential heart failure risk directly from standard chest X-ray images. This tool is ideal for initial cardiac screening workflows where efficiency and early detection of cardiomegaly are crucial.
View qXR-CTR →Choose Lung Density Analysis if…
Choose Lung Density Analysis if you require comprehensive, quantitative analysis and 3D visualization of lung parenchyma from CT scans for the diagnosis and management of chronic lung diseases such as COPD, emphysema, and asthma. This tool is particularly well-suited for detailed pulmonary assessment, including lung cancer screening programs and personalized patient care plans.
View Lung Density Analysis →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | qXR-CTR | Lung Density Analysis |
|---|---|---|
| Deployment | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Lung Density AnalysisTool B (Lung Density Analysis) emphasizes a fully automated solution with no new user interfaces to learn, integrating directly into PACS and returning results without user intervention. While Tool A (qXR-CTR) also automates a specific measurement and aims to reduce workload, Tool B's explicit focus on seamless, no-learning-curve integration for complex 3D visualization and detailed reports gives it an edge in user experience.
Clinical Value
Lung Density AnalysisTool B (Lung Density Analysis) offers broader and deeper clinical utility for pulmonary conditions, providing quantitative analysis, 3D visualization, and specific mapping of various lung components from CT scans for diseases like COPD and emphysema. Its validated use in lung cancer screening and patient counseling reports adds significant value. Tool A (qXR-CTR) is effective for heart failure risk from X-rays, but Tool B's comprehensive analysis for multiple complex lung diseases, including for treatment planning and monitoring, demonstrates greater overall clinical value.
Pricing & Value
TieBoth Tool A (qXR-CTR) and Tool B (Lung Density Analysis) require direct contact for pricing, and no public details are disclosed. While Tool B mentions a subscription-based model, this information is insufficient to conduct a meaningful comparison of their value propositions. Therefore, a winner cannot be determined in this dimension.
Enterprise Readiness
Lung Density AnalysisBoth tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, BAA, and flexible deployment options. However, Tool B (Lung Density Analysis) explicitly lists a wider array of deployment methods, including locally virtualized options (VM, Docker), direct PACS integration, and availability on multiple AI marketplaces/distribution platforms, suggesting a slightly more versatile and integrated approach for diverse enterprise environments.
Innovation
Lung Density AnalysisTool B (Lung Density Analysis) demonstrates a higher degree of innovation through its advanced quantitative analysis, 3D visualization, patented Parametric Response Mapping (PRM) technology for detailed lung component mapping, and Imbio Noise Reduction Technology (NRT) for low-dose scans. While Tool A (qXR-CTR)'s automated CTR measurement is valuable, Tool B's comprehensive and multi-faceted approach to lung disease characterization from CT scans appears more cutting-edge.
Support & Docs
qXR-CTRTool A (qXR-CTR) provides more explicit details about its support structure, including a HelpCenter with user manuals, FAQs, and troubleshooting guides, along with dedicated client success partners and email support with a typical response time of less than 6 hours. Users can also request support, report issues, and send ideas through the app. While Tool B mentions support and FAQs, the level of detail regarding response times or dedicated personnel is not as clear.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | qXR-CTR | Lung Density Analysis |
|---|---|---|
| Name | qXR-CTR | Lung Density Analysis |
| Company | Qure.ai Technologies | IMBIO |
| Primary Focus | Automates the measurement of the cardiothoracic ratio (CTR) for heart size and potential heart failure risk assessment. | Provides quantitative analysis and 3D visualization of lung conditions for diagnosis and management of diseases like COPD and emphysema. |
| Imaging Modality | Chest X-ray images | CT scans |
| Specialties | Cardiology, Radiology | Pulmonology, Radiology |
| Key Features | Not specified | Automated detection, visualization, and quantification of emphysema; Validated for low-dose CT scans in lung cancer screening; Patient-centered LungMapu2122 report for smoking cessation counseling; Fully automated quantitative analysis and 3D visualization to PACS; Imbio Noise Reduction Technology (NRT) for low dose scans; Mapping of normal lung, air-trapping, and emphysema (Functional LDA); Advanced density analysis for COPD, Asthma, BOS; Quantitative reports with coronal, axial, sagittal visuals and bar charts. |
Videos
Demos, reviews, and walkthroughs featuring qXR-CTR and Lung Density Analysis.